Orexo´s Nomination Committee for the Annual General Meeting 2025

Orexo Sweden

(subject "Nomination Committee") at latest March 7, 2025.

Orexo AB (publ.)

Lena Wange, IR & Communications Director
Tel: [phone]
E-mail: [e-mail]

About Orexo

Orexo is a Swedish pharmaceutical company with nearly 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2023 amounted to SEK 639 million, and the number of employees to 116. Orexo is listed on Nasdaq Stockholm's main list and is available as an ADR on OTCQX (ORXOY) in the US.

For more information about Orexo please visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube.

The information was submitted for publication at 8 am CET on October 4, 2024. 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/orexo/r/orexo-s-nomination-committee-for-the-annual-general-meeting-2025,c4046784

 

View original content:https://www.prnewswire.co.uk/news-releases/orexos-nomination-committee-for-the-annual-general-meeting-2025-302267573.html